Patents by Inventor Ruyun Ma

Ruyun Ma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Application of trans-1,3-dilinolein in the preparation of medicaments for treating gastric cancer, stomachic tonic, health products and foods
    Patent number: 11744818
    Abstract: Some embodiments of the disclosure provide new uses of trans-1,3-dilinolein as medicaments and food. In an embodiment, an application of trans-1,3-dilinolein in the preparation of stomachic tonic and an application thereof include the preparation of medicaments for treating gastric cancer. Cell experiments show that trans-1,3-dilinolein promotes the proliferation of human gastric mucosal epithelial cell line GES-1 under normal oxygen and hypoxic conditions and it has concentration-dependent killing effect on human gastric cancer cell line HGC-27 and killing effect on hypoxic gastric cancer cells. At a concentration of 300 ?m and more, trans-1,3-dilinolein kills gastric cancer cells significantly and the killing effect becomes more significant under hypoxic conditions.
    Type: Grant
    Filed: October 14, 2021
    Date of Patent: September 5, 2023
    Assignee: Lanzhou University
    Inventors: Jianye Dai, Zheng Jin, Ruyun Ma, Yanning Zhu
  • Application of Trans-1,3-Dilinolein in the Preparation of Medicaments for Treating Gastric Cancer, Stomachic Tonic, Health Products and Foods
    Publication number: 20220218645
    Abstract: Some embodiments of the disclosure provide new uses of trans-1,3-dilinolein as medicaments and food. In an embodiment, an application of trans-1,3-dilinolein in the preparation of stomachic tonic and an application thereof include the preparation of medicaments for treating gastric cancer. Cell experiments show that trans-1,3-dilinolein promotes the proliferation of human gastric mucosal epithelial cell line GES-1 under normal oxygen and hypoxic conditions and it has concentration-dependent killing effect on human gastric cancer cell line HGC-27 and killing effect on hypoxic gastric cancer cells. At a concentration of 300 ?m and more, trans-1,3-dilinolein kills gastric cancer cells significantly and the killing effect becomes more significant under hypoxic conditions.
    Type: Application
    Filed: October 14, 2021
    Publication date: July 14, 2022
    Applicant: Lanzhou University
    Inventors: Jianye Dai, Zheng Jin, Ruyun Ma, Yanning Zhu